Close
Almac
Achema middle east

India crosses historic one billion COVID-19 vaccine milestone

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

First GLP-1 Pill for Obesity by Novo Nordisk Approved by FDA

The U.S. Food and Drug Administration – FDA on...

How High-Achievers Stay Future-Ready in Evolving Job Markets

Job markets today are transforming rapidly. In the past...

Proactive Risk Management as a Core Capability in Pharma Development

Risk management in pharma is often treated as a reactive compliance box-ticking exercise. This article argues for reframing risk as a strategic competitive advantage. It details proactive frameworks like the "Excipient Exclusion Filter," Decision Quality (DQ) matrices, and "pre-mortem" analyses that allow development teams to anticipate failure modes and engineer them out of the pipeline before they occur.
- Advertisement -

Indian has administered 100 crore doses of the COVID-19 vaccine to its citizens. Netizens took to Twitter to celebrate the historic milestone.

Indian has crossed the historic milestone of administering 100 crore (1 billion) doses of the COVID-19 vaccine to its citizens. Union Health Minister Mansukh Mandaviya took to Twitter to congratulate the country on the occasion. Mandaviya credited Prime Minister Narendra Modi’s leadership for the feat.

The cumulative COVID-19 vaccine doses administered in the country surpassed the 100-crore milestone on Thursday. In a tweet, Union Health Minister Mansukh Mandaviya congratulated the country on achieving the feat, and said it was the result of the able leadership of Prime Minister Narendra Modi. According to official sources, around 75 per cent of India’s all eligible adult population has been administered at least the first dose and around 31 per cent has received both the doses of the vaccine. India took 85 days to touch the 10-crore vaccination mark, 45 more days to cross the 20-crore mark and 29 more days to reach the 30-crore mark, according to the Union Health Ministry data. The country took 24 days to reach the 40-crore mark from 30-crore doses and then 20 more days to surpass the 50-crore vaccination mark on August 6.It then took 76 days to go past the 100-crore mark. The top five states which have administered the highest number of doses are Uttar Pradesh followed by Maharashtra, West Bengal, Gujarat and Madhya Pradesh.

The countrywide vaccination drive was rolled out on January 16 with health care workers (HCWs) getting inoculated in the first phase. The vaccination of frontline workers (FLWs) started from February 2. The next phase of COVID-19 vaccination commenced from March 1 for people over 60 years of age and those aged 45 and above with specified co-morbid conditions. The country launched vaccination for all people aged over 45 years from April 1. The government then decided to expand its vaccination drive by allowing all above 18 to be vaccinated from May 1.

Latest stories

Related stories

First GLP-1 Pill for Obesity by Novo Nordisk Approved by FDA

The U.S. Food and Drug Administration – FDA on...

How High-Achievers Stay Future-Ready in Evolving Job Markets

Job markets today are transforming rapidly. In the past...

Proactive Risk Management as a Core Capability in Pharma Development

Risk management in pharma is often treated as a reactive compliance box-ticking exercise. This article argues for reframing risk as a strategic competitive advantage. It details proactive frameworks like the "Excipient Exclusion Filter," Decision Quality (DQ) matrices, and "pre-mortem" analyses that allow development teams to anticipate failure modes and engineer them out of the pipeline before they occur.

Rethinking Pipeline Value Beyond Peak Sales Forecasts

The traditional reliance on risk-adjusted Net Present Value (rNPV) and peak sales forecasts is failing to capture the true potential of modern pharmaceutical assets, particularly platform technologies. This article introduces holistic valuation frameworks like Real Options Analysis (ROA) and the Platform VISTA model, arguing for a shift toward valuing "strategic fit," "lifecycle potential," and the intangible equity of innovation engines.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »